Clinical Topics & News

Close to Me: CBOC Infusion Program


 

Background

Currently, within the Veterans Affairs Healthcare System, anticancer therapy infusions and injections are primarily offered at VA medical centers (VAMCs) in urban areas. The time and out-of-pocket expenses related to travel present a barrier to care, often leading veterans to seek cancer care in the community. The Minneapolis VA developed a “Remote Infusion” program that deploys a chemotherapy certified RN to administer anticancer and supportive therapies at surrounding Community Based Outpatient Clinics (CBOCs). The program expanded in October 2021, and since, they have provided 259 infusions and injections to 145 veterans at 16 CBOCs. These efforts have saved at least 20,000 miles of travel for veterans in the Minneapolis/ St. Cloud catchment area. Building off the success of this program, the National Oncology Program Integrated Project Team has developed the “Close to Me” CBOC Infusion Program.

Methods

The “Close to Me” CBOC Infusion Program utilizes VAMCs to compound treatments. Then a chemotherapy certified RN is deployed to the surrounding CBOCs to administer treatments. Veterans eligible for this program must have received and tolerated their first dose of treatment at a VAMC. Medications included in this program have low risk of reaction, short infusion time, and at least 8 hours of drug stability. Treatments include immune check point inhibitors, leuprolide, octreotide, IV fluids, and iron infusions. Additional treatments continue to be evaluated and added. Telehealth modalities are utilized for patient visits with their oncology provider for treatment clearance. An implementation toolkit, including a library of standard operating procedures, note templates, and staffing models, has been developed for VAMCs interested in replicating this program.

Results

The Pittsburgh VAMC launched the first “Close to Me” CBOC Infusion Program June 8, 2022.

Conclusions

The “Close to Me” CBOC infusion program optimizes current VA infrastructure and processes to expand access to the world class oncology care VA provides by reducing travel burden for the veterans. Additional areas of novel solutions under development to provide expanded access points to anticancer therapies include mobile infusion units, mobile compounding units, and home administration.

Recommended Reading

Waldenstrom Macroglobulinemia Presenting With Schnitzler Syndrome
AVAHO
Not Just Castleman Disease: an Elusive Diagnosis of TAFRO Syndrome
AVAHO
Demographics in Early vs Late-Stage Laryngeal Squamous Cell Carcinoma: A NCDB Review
AVAHO
Shortened radiotherapy for endometrial cancer looks safe, questions remain
AVAHO
Impact of Insurance Status on Survival in Hurthle Cell Carcinoma: A National Cancer Database (NCDB) Analysis
AVAHO
Financial Toxicity in Colorectal Cancer Patient Who Received Localized Treatment in the Veterans Affairs Health System
AVAHO
Academic/Research Facility Utilization and Survival Outcomes in Osteosarcoma: An NCDB Analysis
AVAHO
New ESC cardio-oncology guideline aims to reduce cardiotoxicity
AVAHO
Evaluating Progression Free Survival Among Veteran Population With Stage IV Non-Small Cell Immunotherapy vs Chemo- Immunotherapy
AVAHO
Improving Veteran Adherence to Preadmission ERAS Protocol: Decreasing Avoidable Surgical Cancellations and Post-Operative Length of Stay (LOS)
AVAHO